



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)


[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PLX5622

## Chemical Properties

CAS No. :	1303420-67-8
Formula:	C <sub>21</sub> H <sub>19</sub> F <sub>2</sub> N <sub>5</sub> O
Molecular Weight:	395.41
Appearance:	no data available
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year



## Biological Description

Description	PLX5622 is a CSF1R inhibitor (IC <sub>50</sub> =0.016 μM) with selectivity, oral activity, and blood-brain barrier permeability. PLX5622 induces sustained and specific elimination of microglia.
Targets(IC <sub>50</sub> )	c-Fms,CSF-1R
In vitro	<p><b>METHODS:</b> CX CR1+/GFP mouse-derived mixed glial cell cultures were treated with PLX5622 (0.1-10 μM) for 7 days and cell counts were assayed by Flow cytometry.</p> <p><b>RESULTS:</b> Although there was a dose-dependent decrease in microglia numbers under PLX5622, no decrease in GFAP+ astrocytes was seen, but rather a gradual increase, along with a decrease in PDGFR-α OPC. [1]</p> <p><b>METHODS:</b> Cerebellar sections prepared from PLP-eGFP mouse pups were treated with PLX5622 (1-20 μM) for 3 days followed by Immunostaining.</p> <p><b>RESULTS:</b> After three days of treatment, PLX5622 at concentrations greater than 2 μM eliminated more than 95% of microglia. [2]</p>
In vivo	<p><b>METHODS:</b> To study in vivo activity, PLX5622 (1200 mg/kg) was administered to PLP eGFP mice by feed for 7-21 days.</p> <p><b>RESULTS:</b> PLX5622 was effective in depleting microglia in the central nervous system of adult mice. treatment with PLX5622 for 7 days had no effect on oligodendrocyte progenitor cell populations; however, a mild reduction was observed after 21 days in some central nervous system regions. [2]</p>

## Solubility Information

Solubility	DMSO: 16.67 mg/mL (42.15 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	2.529 mL	12.6451 mL	25.2902 mL
5 mM	0.5058 mL	2.529 mL	5.058 mL
10 mM	0.2529 mL	1.2645 mL	2.529 mL
50 mM	0.0506 mL	0.2529 mL	0.5058 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

### Reference

Garcia-Agudo LF, et al. Genetically induced brain inflammation by Cnp deletion transiently benefits from microglia depletion. *FASEB J.* 2019 Jul;33(7):8634-8647.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481